KR102306956B1 - 신규한 조성물 및 치료 방법 - Google Patents

신규한 조성물 및 치료 방법 Download PDF

Info

Publication number
KR102306956B1
KR102306956B1 KR1020187031371A KR20187031371A KR102306956B1 KR 102306956 B1 KR102306956 B1 KR 102306956B1 KR 1020187031371 A KR1020187031371 A KR 1020187031371A KR 20187031371 A KR20187031371 A KR 20187031371A KR 102306956 B1 KR102306956 B1 KR 102306956B1
Authority
KR
South Korea
Prior art keywords
compound
compounds
present
delete delete
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187031371A
Other languages
English (en)
Korean (ko)
Other versions
KR20180125583A (ko
Inventor
수치스미타 아차리아
산토쉬 케이. 판다
프라그냐 다스
비먼 아가왈
Original Assignee
아유비스 리서치, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아유비스 리서치, 인코포레이티드 filed Critical 아유비스 리서치, 인코포레이티드
Priority to KR1020217030430A priority Critical patent/KR102532825B1/ko
Publication of KR20180125583A publication Critical patent/KR20180125583A/ko
Application granted granted Critical
Publication of KR102306956B1 publication Critical patent/KR102306956B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187031371A 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법 Active KR102306956B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217030430A KR102532825B1 (ko) 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662315144P 2016-03-30 2016-03-30
US62/315,144 2016-03-30
PCT/US2017/024908 WO2017173024A1 (en) 2016-03-30 2017-03-30 Novel compositions and therapeutic methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030430A Division KR102532825B1 (ko) 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법

Publications (2)

Publication Number Publication Date
KR20180125583A KR20180125583A (ko) 2018-11-23
KR102306956B1 true KR102306956B1 (ko) 2021-10-01

Family

ID=59958482

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187031371A Active KR102306956B1 (ko) 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법
KR1020217030430A Active KR102532825B1 (ko) 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217030430A Active KR102532825B1 (ko) 2016-03-30 2017-03-30 신규한 조성물 및 치료 방법

Country Status (10)

Country Link
US (1) US11207343B2 (https=)
EP (1) EP3436467B1 (https=)
JP (5) JP2019513137A (https=)
KR (2) KR102306956B1 (https=)
CN (2) CN114712383B (https=)
AU (4) AU2017244114B2 (https=)
BR (1) BR112018067833B1 (https=)
CA (2) CA3128743C (https=)
MX (1) MX392849B (https=)
WO (1) WO2017173024A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
US20220143059A1 (en) * 2016-03-30 2022-05-12 Ayuvis Research, Inc. Compositions and therapeutic methods
US12594286B2 (en) 2018-07-02 2026-04-07 Ayuvis Research, Inc. Immunodulating small molecules
KR20210027381A (ko) * 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3820512B1 (en) * 2018-07-02 2024-04-24 Ayuvis Research, Inc. Immunomodulating compositions comprising oligosaccharide derivatives
JP7382281B2 (ja) * 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
JP7382280B2 (ja) 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
WO2022169855A1 (en) * 2021-02-04 2022-08-11 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
WO2023086877A1 (en) * 2021-11-12 2023-05-19 Ayuvis Research, Inc. Novel compositions and therapeutic methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070500A1 (en) 2001-12-13 2005-03-31 Boucher L Isabelle Method of modulating release of saccharides and uses thereof
US20050158814A1 (en) 2002-04-29 2005-07-21 Aerts Johannes Maria Franciscus G. Means and methods for detecting endoglycosidase activity
WO2007048974A2 (fr) * 2005-10-24 2007-05-03 Universite Claude Bernard Lyon I Heterooligomeres de d-glucosamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation
JP2007246426A (ja) 2006-03-15 2007-09-27 Shinshu Univ Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
US20130281395A1 (en) 2010-09-24 2013-10-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4152413A (en) 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4621075A (en) 1984-11-28 1986-11-04 The Procter & Gamble Company Gel-form topical antibiotic compositions
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
JPH0615476B2 (ja) * 1985-05-22 1994-03-02 イハラケミカル工業株式会社 抗感染症剤
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
FR2640627A1 (fr) * 1988-12-16 1990-06-22 Commissariat Energie Atomique Nouveaux fluorures d'aldosaminyle, leur preparation et leur utilisation pour la fabrication d'oligosaccharides amines lies (1 -> 4)
US5932640A (en) 1989-01-21 1999-08-03 Clariant Finance (Bvi) Limited Dyeability or mass coloration of synthetic polyamide
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
JPH041115A (ja) 1990-04-13 1992-01-06 Pola Chem Ind Inc 皮膚外用剤
EP0570682B1 (en) 1992-05-07 1997-07-23 American Cyanamid Company Synthetic lipid A glycoconjugate antigens for use in vaccines
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AU7484198A (en) 1997-05-12 1998-12-08 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
US6492350B2 (en) 2000-01-27 2002-12-10 Jdc (Hawaii) Inc. Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US7098195B2 (en) * 2001-11-28 2006-08-29 Health Research, Inc. Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
EP1440683A1 (de) 2003-01-23 2004-07-28 Cognis France S.A. Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen
CA2428744C (en) 2003-01-24 2013-06-25 University Of Manitoba Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction
US20050255048A1 (en) 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
JP5035787B2 (ja) 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
GB0622688D0 (en) * 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
ES2543063T3 (es) * 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
CN101732338A (zh) 2008-11-26 2010-06-16 中国科学院大连化学物理研究所 壳六糖在制备预防血管生成的药物中的应用
CN102475714A (zh) 2010-11-29 2012-05-30 中国科学院大连化学物理研究所 壳寡糖单一化合物在免疫增强药物中的应用
WO2012129802A1 (en) * 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
EP2885323B1 (en) 2012-08-17 2023-08-30 The University of North Carolina At Chapel Hill Water soluble nitric oxide-releasing polyglucosamines and uses thereof
EP3001838A4 (en) 2013-05-14 2017-02-08 Medlmmune, LLC Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses therof
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
JP7246205B2 (ja) * 2019-02-27 2023-03-27 センクシア株式会社 デッキプレート

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070500A1 (en) 2001-12-13 2005-03-31 Boucher L Isabelle Method of modulating release of saccharides and uses thereof
US20050158814A1 (en) 2002-04-29 2005-07-21 Aerts Johannes Maria Franciscus G. Means and methods for detecting endoglycosidase activity
WO2007048974A2 (fr) * 2005-10-24 2007-05-03 Universite Claude Bernard Lyon I Heterooligomeres de d-glucosamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation
JP2007246426A (ja) 2006-03-15 2007-09-27 Shinshu Univ Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
US20130281395A1 (en) 2010-09-24 2013-10-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carbohydrate Research. 2005. Vol.340. No.12, pp.1983-1996.
FASEB Journal. 2014. Vol.28, No.1, Supplement 837.8*

Also Published As

Publication number Publication date
EP3436467B1 (en) 2025-08-06
JP7594268B2 (ja) 2024-12-04
EP3436467A4 (en) 2020-03-18
JP7774885B2 (ja) 2025-11-25
CA3015494C (en) 2021-10-26
JP7357364B2 (ja) 2023-10-06
JP2020193215A (ja) 2020-12-03
AU2017244114B2 (en) 2021-07-22
MX2018009802A (es) 2018-12-06
AU2017244114A1 (en) 2018-11-08
KR20210122865A (ko) 2021-10-12
MX392849B (es) 2025-03-24
JP2020090675A (ja) 2020-06-11
CN108884121A (zh) 2018-11-23
AU2023222844A1 (en) 2023-09-14
KR20180125583A (ko) 2018-11-23
AU2021232715A1 (en) 2021-10-14
BR112018067833A2 (pt) 2019-03-19
CA3015494A1 (en) 2017-10-05
US11207343B2 (en) 2021-12-28
JP2023179505A (ja) 2023-12-19
US20170281667A1 (en) 2017-10-05
EP3436467C0 (en) 2025-08-06
CA3128743A1 (en) 2017-10-05
CN108884121B (zh) 2022-05-31
BR112018067833B1 (pt) 2024-03-05
AU2025205307A1 (en) 2025-07-31
JP2019513137A (ja) 2019-05-23
CN114712383A (zh) 2022-07-08
CA3128743C (en) 2024-06-25
CN114712383B (zh) 2024-09-24
KR102532825B1 (ko) 2023-05-17
EP3436467A1 (en) 2019-02-06
JP2024041834A (ja) 2024-03-27
WO2017173024A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
KR102306956B1 (ko) 신규한 조성물 및 치료 방법
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
JP7695277B2 (ja) 安定なペプチド組成物
US20080286211A1 (en) Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function
WO2012038058A1 (en) Treatment of conditions by toll-like receptor modulators
KR20210027381A (ko) 신규 면역조절 소분자
KR20170030093A (ko) 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
UA126941C2 (uk) Фармацевтичні композиції для інгібування запальних цитокінів
WO2019010484A2 (en) SYNTHETIC BIOCONJUGATES
JP2001010971A (ja) 眼感染症治療用眼軟膏剤
EP3233102B1 (en) Use of an antimicrobial peptide to induce cell death in breast cancer
HK40004181A (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
HK40004181B (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
ITMI20080289A1 (it) Composizioni di gemifloxacina con elevata efficacia su patologie oculari
AU2022383860A1 (en) Novel compositions and therapeutic methods
US20220143059A1 (en) Compositions and therapeutic methods
IL298323B2 (en) A method for treating lysosomal storage disease using histatin peptides

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20181029

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181029

Comment text: Request for Examination of Application

AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200228

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210225

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210225

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200929

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20181114

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20181029

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210623

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210527

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210225

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200929

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20181114

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20181029

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210923

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210924

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration